Provided by Tiger Trade Technology Pte. Ltd.

Sanofi SA

40.23
+0.03000.07%
Post-market: 40.360.1300+0.32%19:53 EDT
Volume:3.00M
Turnover:119.63M
Market Cap:96.39B
PE:21.58
High:40.27
Open:40.18
Low:39.58
Close:40.20
52wk High:52.68
52wk Low:39.18
Shares:2.40B
Float Shares:2.16B
Volume Ratio:0.75
T/O Rate:0.14%
Dividend:2.37
Dividend Rate:5.88%
EPS(TTM):1.86
EPS(LYR):3.76
ROE:5.71%
ROA:5.09%
PB:1.24
PE(LYR):10.70

Loading ...

Sanofi appoints Belén Garijo CEO, effective May 1, 2026

Reuters
·
May 05

Sanofi invests C$294M to expand AI Center of Excellence in Toronto

TIPRANKS
·
May 05

European Equities Traded in the US as American Depositary Receipts Start Week Lower

MT Newswires Live
·
May 04

Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe

Benzinga Earnings
·
Apr 30

Sanofi appoints Belén Garijo CEO, effective May 1

Reuters
·
Apr 30

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

Dow Jones
·
Apr 29

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

Dow Jones
·
Apr 27

Sector Update: Health Care

MT Newswires Live
·
Apr 25

Sanofi Prices $2.7 Billion in Bonds in Three-Part Offering

MT Newswires Live
·
Apr 25

Sanofi Says Secondary Progressive Multiple Sclerosis Treatment Recommended for Approval in EU

MT Newswires Live
·
Apr 24

European Equities Traded in US as ADRs Ease in Thursday Trading

MT Newswires Live
·
Apr 23

Sector Update: Health Care Stocks Decline Premarket Thursday

MT Newswires Live
·
Apr 23

Sanofi SA reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
Apr 23

Analysts Conflicted on These Healthcare Names: Sanofi (SNY), BrightSpring Health Services, Inc. (BTSG) and Collegium Pharmaceutical (COLL)

TIPRANKS
·
Apr 23

Sanofi's Dupixent Success Masks R&D Concerns as New CEO Takes the Helm

Stock News
·
Apr 23

Sanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision

Benzinga_recent_news
·
Apr 22

Sanofi Says Tzield Gets US Approval to Delay Stage 3 Type 1 Diabetes Onset in Young Children

MT Newswires Live
·
Apr 22

Sanofi SA expected to post earnings of $1.03 a share - Earnings Preview

Reuters
·
Apr 21

Sanofi Says Its COVID-19 Vaccine Shows Better Tolerability Than Moderna Alternative in Phase 4 Trial

MT Newswires Live
·
Apr 20

Sanofi says COVID-19 vaccine showed better tolerability than Moderna’s

TIPRANKS
·
Apr 18